25 February 2021

Renewed funding paves way for implementation of Consortium’s access program

The Pediatric Praziquantel Consortium has received renewed funding from the Global Health Innovative Technology (GHIT) Fund and the European & Developing Countries Clinical Trials Partnership (EDCTP) for the implementation of its access program, ADOPT, to prepare for the large-scale delivery of a new child-friendly medication to treat schistosomiasis in preschool-age children.

The project has progressed to Phase III, with a pivotal trial being run in Kenya and Ivory Coast to generate confirmatory data for registration. Through its ADOPT program, the Consortium aims to identify approaches to ensure widespread acceptance and equitable access to its pediatric treatment across endemic countries, once registered.

Read the Consortium’s full press release here. Also available in French, Japanese and Portuguese.